

General description

Immunoglobulin therapy, also known as normal human immunoglobulin (NHIG), is the use of a mixture of antibodies (immunoglobulins) to treat primary immunodeficiency and Kawasaki disease.

| | |
|--------------------|---|
| ATC codes | J06BA02 |
| Medicine type | Biological agent |
| EML status history | First added in 1977 (TRS 615) for Primary immunodeficiencies Added in 1977 (TRS 615) for Mucocutaneous lymph node syndrome Removed in 2003 (TRS 920) for Primary immunodeficiencies Removed in 2003 (TRS 920) for Mucocutaneous lymph node syndrome Added in 2007 (TRS 946) for Primary immunodeficiencies Added in 2007 (TRS 946) for Mucocutaneous lymph node syndrome Added in 2023 (TRS 1049) for Langerhans cell histiocytosis |
| Wikipedia | Normal immunoglobulin  |
| DrugBank | Normal immunoglobulin (Immune Globulin Human)  |

Recommendations

Section [Human immunoglobulins](#)

Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Parenteral > General injections > IM: 16% protein solution

Parenteral > General injections > SC: 15% protein solution; 16% protein solution

Indications

[Primary immunodeficiencies](#)

[Mucocutaneous lymph node syndrome](#)

[Langerhans cell histiocytosis](#)

